^
Association details:
| Biomarker: | CLDN18.2 positive |
|---|---|
| Cancer: | Gastroesophageal Junction Adenocarcinoma |
| Drug: | AB011 (CLDN18.2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A multicenter, phase 1 study of AB011, a recombinant humanized anti-CLDN18.2 monoclonal antibody, as monotherapy and combined with capecitabine and oxaliplatin (CAPOX) in patients with advanced solid tumors.
Published date:
01/17/2023
Excerpt:
Among 23 pts who had at least one tumor assessment by the data cut-off, 8/13 (61.5%) in 20mg/kg group and 7/10 (70%) in 30mg/kg group achieved PR. The ORR and DCR were 65.2% and 100% respectively….These results indicate that AB011, either in monotherapy or combined with chemotherapy, had a manageable safety profile and encouraging efficacy in CLDND18.2 positive advanced GC/GEJA and PC.
Secondary therapy:
CAPOX
DOI:
10.1200/JCO.2023.41.3_suppl.391
Trial ID:
